An introduction to the mechanism of action and therapeutic advantages of the FLT3 inhibitor Quizartinib

In recent years, targeted therapy has made major breakthroughs in the field of acute myeloid leukemia (AML), especially the treatment of FLT3 gene mutations. Among them, Quizartinib (Quizartinib), as a highly selective FLT3 inhibitor, has become an important tool to deal with FLT3-ITD mutations AML. This article will systematically introduce quizartinib’s mechanism of action, clinical efficacy, comparative advantages compared with other drugs, and its positioning in treatment plans to help patients and doctors understand this emerging treatment method more comprehensively.

1. FLT3Mutation background and treatment challenges

FLT3 (FMS-like tyrosine kinase3) is a receptor tyrosine kinase widely expressed in hematopoietic stem cells. During normal hematopoiesis, the FLT3 signaling pathway regulates cell proliferation and differentiation. When FLT3 is mutated (especially internal tandem repeat mutations, FLT3-ITD), the receptor will be continuously activated, causing leukemia cells to continue to divide and lose their ability to differentiate, thereby accelerating the progression of AML.

About30% of AML patients carry FLT3 mutations, among which FLT3-ITD mutations are associated with poor prognosis, such as high recurrence rate, short survival, and low sensitivity to traditional chemotherapy. Therefore, the development of targeted inhibitors targeting FLT3 mutations has become an important direction in the current treatment of acute myeloid leukemia.

2. Mechanism of action of Quizartinib

Quizatinib is a second-generation, highly selective FLT3 inhibitor specifically designed to target FLT3 mutations, specifically FLT3-ITD . It binds to the ATP binding site of FLT3kinase and blocks its tyrosine kinase activity, thereby inhibiting the activation of the FLT3 signaling pathway.

Specific mechanisms include:

Inhibits the phosphorylation of mutantFLT3 and terminates the conduction of key signals such as downstream STAT5, ERK and PI3K/AKT;

Induces leukemia cell apoptosis and inhibits their proliferation and survival;

Reduce the number of leukemia cells in bone marrow and peripheral blood, and promote the recovery of normal function of the hematopoietic system.

Compared with first-generation FLT3 inhibitors (such as sorafenib), quizartinib is more potent and more selective in inhibiting FLT3-ITD, and has less impact on wild-type FLT3 and other kinases, so side effects are more controllable.

3. Clinical research and efficacy performance of quizartinib

The efficacy of quizartinib has been confirmed in multiple international clinical studies, the most representative of which are the two pivotal III clinical trials QUANTUM-R and QUANTUM-First.

1.QUANTUM-RStudy (Relapsed/RefractoryAML)

This study compares the efficacy of quizartinib alone with traditional chemotherapy in patients with relapsed / refractory AML mutations. The results showed that the median overall survival time (OS) of the quizartinib group was significantly higher than that of the chemotherapy group (6.2 months vs 4.7 months), and the complete remission rate (CR) has also improved, proving its high clinical value in the treatment of refractory AML.

2.QUANTUM-FirstStudy (Initial TreatmentAML)

This study evaluates the efficacy of quizartinib in combination with standard chemotherapy (eg, cytarabine+daunorubicin) in patients with newly diagnosedFLT3-ITD AML. The results show that the quizartinib combination regimen can significantly prolong relapse-free survival (EFS) and overall survival (OS), and the response rate is close to 70%. This led to Quizartinib being considered as having potential as a standard component of initial treatment.

4. Treatment advantages and positioning

Compared with otherFLT3 inhibitors such as Midostaurin (Midostaurin) and Gilitinib (Gilteritinib), Quizartinib has the following therapeutic advantages:

1.Higher selectivity and inhibition strength

Quizatinib has a stronger affinity forFLT3-ITD and less interference with other kinase activities, which means lower off-target risk and better safety. This is particularly important during long-term use or combination therapy.

2.Can be used for multi-stage treatment

Whether it is first-line combination therapy for newly diagnosed patients or single-agent salvage therapy for relapsed and refractory patients, quizartinib has shown good efficacy. This broad applicability makes it an important drug throughout the entire treatment process of AML.

3. Convenient to take orally, high compliance

Quizartinib is an oral preparation that is easy to take and suitable for patients with long-term maintenance treatment or outpatient treatment. It can significantly improve patients' quality of life and compliance.

4. Effective against multiple mutation subtypes

In addition to FLT3-ITD mutations, quizartinib has also shown some activity against certain TKD (tyrosine kinase domain) mutations, which makes it also have certain application potential in AML with complex genetic backgrounds.

5. Adverse reactions and medication precautions

Although quizartinib is generally well tolerated, there are some possible side effects that you should be aware of during use:

1.QTInterval prolongation: ECG needs to be monitored regularly during treatment;

2.Neutropenia and thrombocytopenia: Close monitoring is required when combined with myelosuppressive drugs;

3.Gastrointestinal reactions: such as nausea, diarrhea, etc., can be improved through symptomatic treatment;

4.Skin reactions, fatigue, etc. are also common adverse reactions, usually mild to moderate.

It is recommended that patients undergo detailed molecular testing to determine their FLT3 mutation status before receiving quizartinib treatment, and develop individualized treatment plans under the guidance of professional doctors.

Quizatinib, as a highly selective FLT3 inhibitor, is changing the treatment landscape of FLT3mutated AML with its precise targeting mechanism and significant clinical efficacy. Its emergence not only brings new hope to patients with relapsed or refractory AML, but has also gradually become a new standard of combination therapy for newly treated patients. With the accumulation of more real-world data and the advancement of combination strategies such as immunotherapy, quizartinib is expected to play a greater role in the precision treatment of AML, pushing the treatment of this difficult-to-treat hematological tumor into a new era.

Reference materials:https://www.drugs.com/